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Liver cancer is one of the main causes of cancer-related deaths in men and women around the 
world, with its high mortality rate attributed to its advanced stage at presentation and the lack of 
effective medical therapies. Most cases (75–80%) are classified as hepatocellular carcinomas 
(HCC), which typically develops secondary to a viral hepatitis B or C infection or cirrhosis. Among 
non-HCC liver cancers, cancer of the bile duct (cholangiocarcinoma; CC) is the most common type 
(10%). Increased incidence of CC over the last 30 years, along with identification of rare mixed 
HCC-CC tumors, have highlighted a knowledge gap regarding the molecular mechanisms behind 
the formation of liver tumors. More information is therefore needed to improve the treatments for 
these cancers. Drs. Shelli Morris and William Grady in the Clinical Research Division addressed this 
issue in a recent publication in Oncogene, specifically looking at the interplay between phosphatase 
and tensin homolog (Pten), a protein that inhibits signaling through the PI3K pathway, and 
transforming growth factor β (TGF-β). 
The PI3K/Pten pathway has been shown to regulate the internal conditions in many organs and to 
affect tumor formation in various tissues in mouse models, for instance controlling normal liver 
development and differentiation of liver cells such as hepatocytes and cholangiocytes. In humans, 
the expression of the PTEN gene, which encodes the protein PTEN, is suppressed in almost half of 
all liver cancers, and about 4–5% of all liver cancers have mutant PTEN. Another key player in the 
liver is TGF-β, which together with its cell signaling family members affects the formation of liver 
cancer in a complex and sometimes contradictory manner; it appears to be able to either suppress 
or promote liver tumors, depending on the tissue microenvironment and parallel concurrent gene 
mutations. 
Together with colleagues at University of Washington and the National Cancer Center in Goyang, 
Republic of Korea, the Fred Hutch investigators developed a new mouse liver cancer model and 
carried out a series of studies to analyze how HCCs and CCs that are established 
through Pten inactivation are affected by TGF-β signaling. They found that when TGF-β receptor 2 
(Tgfbr2) was inactivated in mice with simultaneous liver-specific Pten loss, the overall incidence of 
tumors increased to 86% (25/29), as compared to 67% (20/30) of mice with Pten deletion alone. In 
addition to the increased tumor incidence, they observed a dramatic shift in the distribution of tumor  
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types for the double-inactivated livers; more specifically, the number of CCs was significantly 
greater. The latter finding spurred the researchers to look more closely at the expression of a subset 
of markers for liver progenitor/stem cells, i.e. cells that can develop into specialized cell types and 
divide to produce more stem cells. They discovered that the markers c-Kit and CD133 were notably 
increased in mice with inactivated TGF-β signaling. In the double knock-out mice the same was also 
true for the markers Scf and EpCam. This suggests that the histologic shift in tumor types was 
influenced by the deregulated signaling pathways, which in turn influenced the destiny of the cancer 
stem cells. 
"Our results highlight the role that alterations in factors that regulate stem cell fate has on the 
formation of hepatocellular carcinoma and of cholangiocarcinoma," said Dr. Morris. "Furthermore, 
this work highlights the cooperation of multiple signaling pathways in controlling the specification of 
the ultimate tumor type that develops." 
Besides increasing knowledge about the signaling pathways that affect the formation of various 
forms of liver cancer, the developed mouse model provides insights into tumor formation resulting 
from chronic inflammation in the liver. Drs. Morris, Grady and colleagues concluded 
that Pten inactivation likely contributed to the development of inflammatory fatty changes in the liver 
that may have affected the development of HCC, CC and other tumors. 
The research team will continue to investigate the influence of cell signaling proteins and growth 
factors on tumor formation, hopefully leading to more effective targeted therapies. Dr. Morris 
concludes: "Understanding how different signaling pathways control cell specification may help us 
target cancers of a certain lineage more specifically. Our results also suggest that TGF-β signaling 
and PI3K signaling alterations may play a role in the etiology of hepatocellular carcinoma and 
cholangiocarcinoma, which may lead to novel liver cancer prevention strategies." 
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Image provided by Dr. Shelli Morris. 
A representative liver section from a Pten;Tgfbr2 double-
knockout specimen exhibiting focal cholangiocarcinoma 
with invasion into the neighboring hepatic parenchyma 
(arrow). The upper panel shows a low power (5×) view; 
the lower panel shows a high power (20×) view of the 
boxed area. 
 
